1-866-598-7166

Trials for patients who have not had any previous drug treatment

A Study of BMS-986488 as Monotherapy and Combination Therapy in Patients with Advanced Malignant Tumors

[vc_row][vc_column][vc_column_text css=""] Background: BMS-986488 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies. Nivolumab (Opdivo®) is an immunotherapy that works by boosting the body's immune system to recognize and attack cancer cells. Since this...

A Study of Belzutifan + Lenvatinib + Pembrolizumab versus Lenvatinib + Pembrolizumab for Patients with Advanced Kidney Cancer

Background: Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor (TKI) that prevents the growth of cancer cells by blocking the formation of new blood vessels in tumours. It is similar to other approved medications such as Sunitinib (Sutent®) or Axitinib (Inlyta®). Pembrolizumab (Keytruda®) is an immunotherapy drug that is...

Kidney Cancer Canada